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Abstract
The relation of atherosclerotic cardiovascular disease (ASCVD) to not only 
traditional but also new and emergent risk factors has been assessed in aircrew. 
Total flight hours (TFH), high altitude and weightlessness exposure have been 
accounted among traditional risk factors for CVD among the aircrew. The risk 
factors do not perform in loneliness. To predict the 10 years global CV risk, several 
scores are being applied either based on traditional CVD risk factors only or also 
including new and emergent risk factors. To prevent aircrew from developing CVD, 
one should focus on the control of behavioral and metabolic risks as well as the 
polymorphe treatment of high CV risk individuals.
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1. Introduction
Aircrew represent a particular group among “ high cardiovascular disease (CVD) 
risk individuals”. In addition to common life strain, aircrew face typical stress such as 
repeatedly proficiency simulator checks, intermittent medical exams and total flight 
hour obligations, employer pressure, responsibility, and scheduled accomplishment. 
These factors may lead to CVD, either directly or indirectly. They interact with 
traditional risk factors (genetic risk factors: aging, gender, ethnicity, chromosomes, 
HLA, genes, inflight incapacitation) and behavioral risk factors (inactivity, alcohol 
drinking, smoking, unhealthy diet) and emerging cardiovascular risk factors. The 
consequence is cardiovascular remodeling triggered by oxidative stress, inflam-
mation and endothelial dysfunction. Unexpected in-flight medical incapacitation 
or distraction of a pilot may result in aviation accident, which is of public interest, 
harming himself, aircrafts, passengers and environment. Notwithstanding progress 
in prevention and early disease intervention, ischemic events secondary to coronary 
artery disease (CAD) remains among the commonest causes of unheralded acute 
incapacitation in the Western population. Thus, aeromedical providers should help 
aircrew to prevent CVD. It is essential to assess and stabilize the patient, control risk 
factors and optimize pharmacological treatments. Controlling weight and manag-
ing obesity, providing healthy diet and promoting physical activity, and educating 
 aircrew and instituting home-based care monitoring is an important tool to prevent-
ing CVD. Aircrew with CVD are at high-risk and require a multifaceted and multi-
disciplinary intervention that should be started as soon as possible.
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The health of aircrew is an imperative requirement for safe travels of millions 
of people worldwide. The presence or development of CVD in aircrew, with the 
risk of potential clinical manifestations, continues to be a major concern to aviation 
medical practitioners. Despite the rigorously medical screen of pilots compared 
with several other professions, the presence of multi-crew environment, and the 
cockpit resource management with incapacitation training, acute coronary artery 
events remain an important cause of in-flight incapacitation or distraction ending 
in aircraft accidents and fatalities [1]. Few, if any, aircrew involved in accidents and 
incidents suffer from antecedent symptomatic coronary disease. Cardiovascular 
incapacitation of a pilot though rare event represents a seriously potential threat for 
flight safety [2]. In addition, CVDs linked to unexpected in-flight medical incapaci-
tation or impairment account for half of human factor-related causes of aviation 
accidents [1]. In military operation, using single-pilot, high-performance aircraft, 
and even in dual-pilot, cardiac events were found to be second cause of aircraft 
accidents due to acute incapacitation [3].
From 1962 to 2015, Gray et al. listed 10 accidents and incidents in commercial 
passenger flights related to coronary artery events which concerned either the com-
mandant or the first officer and resulted in 240 fatalities [4]. Moreover, 10 out of 
the 98 in-flight medical events addressed by the Australian Transport Safety Bureau 
(ATSB) between 1 January 1975 and 31 March 2006, consisted of heart attack 
explaining the high-observed mortality rate [5]. Autopsy studies of young military 
personnel and aircrew have demonstrated atherosclerosis as a common finding, 
including cases of severe disease and aeromedically disqualifying findings [6–8].
2. Epidemiology of risk factors for cardiovascular disease in aircrew
2.1 Traditional risk factors for cardiovascular disease in aircrew
Several studies mentioned the established risk factors for CVD continuum 
including hypertension, type-2 diabetes, dyslipidemia, smoking, overweight and 
mainly abdominal adiposity, physical inactivity and Mets [9]. Recent data suggest 
disturbing increases in the prevalence of these risk factors for CVD (Figure 1) [10].
2.1.1 Hypertension
Worldwide, hypertension is the leading etiology of morbidity and mortality 
[11, 12]. Hypertension is the first issue for pilots to secure their medical certificate 
[1, 13]. Through complications such as myocardial infarction, stroke, renal failure 
and death, hypertension constitutes a risk of in-flight incapacitation. In-flight CV 
events are believed to be scarce although allegation of in-flight CV incapacitation 
misdiagnosis has once been put forth [14]. Exposure to flight stress could be listed 
as a plausible explanation as weighted by total flight time at baseline. Indeed, 
considering the responsibility to fly the plane, flight crew is exposed to chronic 
stress that might trigger both hypothalamo-pituitary- adrenocortical and sympa-
tho-adreno-medullary pathways to raise arterial blood pressure. In addition, it has 
been reported that chronic stress could lead to hypertension, which is triggered by 
angiotensin II through either lymphocyte T activation or vascular inflammation.
2.1.2 Types-2 diabetes
Type-2 diabetes either through chronic complications (heart disease, hyperten-
sion, and stroke) or acute complications (hypoglycemia or hyperglycemia episodes) 
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can grievously compromise flight safety and harm not only the aircrew himself 
but also the passengers, the aircraft, and the environment [15]. The relationship 
between blood glucose control and the establishment of CVD in diabetes remains 
a matter of controversy. Whilst several glucose-lowering trials in diabetes showed 
significant reduction in microvascular complications, they systematically failed to 
achieve significantly in macrovascular complications. Still, it should be mentioned 
that some systematic reviews and meta-analysis have recommended that efforts to 
improve blood glucose lower the incidence of CVD [16].
2.1.3 Smoking
Smoking has long been considered as the major risk factor for the establish-
ment of CVD. Tobacco use, the single largest preventable cause of CV morbidity, 
is responsible for 10% of all of CVDs and doubles the 10-y mortality rate [17]. 
Worldwide, nearly a billion people are smokers and newly smokers are men from 
low- and middle-income countries (LMICs). Smoking delirious effect is dose 
related with no safe limit observed. It has been shown that passive smoking pro-
duces noticeable interferences in the normal autonomic nervous system functioning 
characterized by increased sympathetic drive and reduced HR variability (HRV) 
and parasympathetic modulation.
2.1.4 Overweight/obesity
Obesity, a significant determinant of CVDs, is extensively related to hyperten-
sion even if the exact mechanisms remain not totally unraveled [18]. This relation 
should now focus on weight variation across time along with visceral or intra-
abdominal fat that is likely linked to the insulin resistance syndrome, an indicator 
of generalized metabolic disorder [18]. Obesity interacts with aviation duties. In 
fact, not only does obesity increase the risk of sudden CV incapacitation, but the 
risk of sudden and subtle incapacitation consequential to sleep apnea and the risk of 
pulmonary embolus do [19]. On the other hand, obesity can jeopardize the egress of 
Figure 1. 
Relationship between risk factors and CVD among aircrew. ASCVD: atherosclerotic cardiovascular disease; 
CVD: cardiovascular disease; TFH: total flight hours.
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aircraft in emergency [19]. The current results demonstrated that short term com-
mercial flying significantly altered cardiovascular function including the reduction 
of parasympathetic modulations. Further, greater physical fitness and lower body 
fat composition were associated with greater cardiac autonomic control for pas-
sengers during flights. Enhanced physical fitness and leaner body composition may 
enable passengers to cope better with the cardiovascular stress and high allostatic 
load associated with air travel for enhanced passenger well-being [20]. In an obser-
vational cross-sectional study among Brazilian pilots, Palmeira found that more 
than half of and nearly a quart pilots were overweighed and obese, respectively. 
These authors concluded that overweight and obesity among the commercial airline 
pilots was high and represents a serious health problem in this population [21].
2.1.5 Physical inactivity
The lack of physical activity has contributed increasingly to overweight and 
obesity in young persons and adults. Physical activity is significant for primary and 
secondary prevention as well notwithstanding of BMI. Aircrew have little physical 
activity and eat higher caloric foods away from home at unscheduled time intervals 
[21]. Physical inactivity and unhealthy diet are responsible of raised BP, increased 
blood glucose, increased blood lipids, and overweight and obesity.
2.1.6 Total flight hours
The relationship between higher TFH and ASCVD risk in pilots have been 
established [22] as well as how TFH expresses the likelihood of crash involvement 
significantly compared with aging, which encompasses a conflict between decreas-
ing cognitive functions that jeopardizes flight safety and increasing flying expertise 
that enhances fight safety [23]. Similarly, having 5,000 tfh or more protects against 
crash involvement but this protection levels off at a threshold of 10,000 tfh [23]. 
Likewise, inverse nonlinear relationship has been found between crash involvement 
and total flight time [23].
2.1.7 High altitude exposure
Pilots have to cope with stress due to 6,000 to 8,000 feet pressurized environ-
ment, and working hours [21]. It is known that the increase of BP with high altitude 
exposure 3000 m above sea level (asl) [24]. The explanation among several is 
the sympathetic activation (increased BP, HR, cardiac output, myocardial twist) 
through peripheral chemoreceptor [24]. Individuals with grade 2 hypertension 
and increased ASCVD risk should check their BP values before and during HA 
(>2500 m) exposure. Individuals with grade 1 hypertension may reach very HA 
(>4000 m) with adequate medical therapy; uncontrolled severe hypertensive 
individuals (grade 3) should avoid exposure to very HA [24]. At HA, left ventricular 
experiences changes such as an increase of systolic function with elevated sphericity 
index, but a decrease of diastolic function [25, 26]. Moreover, HA exposure may 
increase risk of cerebral ischemia for individuals with antecedent of ischemic stroke 
[26–28]. Background contributors are increased hematocrit and greater blood 
viscosity. HA exposure increases risk of hemorrhagic stroke in those with cerebral 
aneurysms and arterial/venous malformation [29]. HA may be at benefit for 
arrhythmia [24]. High altitude less than 4000 m does not affect pacing and implant-
able cardioverter devices [30].
At sea level, barometric pressure is 760 mmHg, and air has a partial pres-
sure of oxygen (PO2) of 160 mmHg. Airline flight usually cruises at altitudes 
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of 9,150–13,000 m (30–40,000 feet) asl where the atmospheric PO2 is usually 
≤38 mmHg, which would normally result in a lethal level of airway (alveolar) 
hypoxia. Aircraft cabins are therefore environmentally modified (pressurized) to 
atmospheric pressures of 1,530–2,440 m (5,000–8,000 feet) asl [24].
2.1.8 Weightlessness exposure
Microgravity is a concern as it affects the entire body’s systems, especially the 
cardiovascular system. Even with very short-duration exposure to microgravity, the 
cardiovascular system meets the return to gravity with CV deconditioning [24].
2.2 New and emergent risk factors for cardiovascular in aircrew
Atherosclerotic cardiovascular disease (ASCVD) starts at a very young age and 
progresses over time allowing sufficient time for screening and early detection of 
the condition. Because CVD often appears in individuals with lower CVD risk, 
some other markers should be able to provide added information about individual’s 
risk, above and beyond the traditional risk factors at baseline. Among them are 
hs-CRP, intima-media thickness (CIMT), LVH, faster HR, kidney dysfunction, 
carotid ankle-brachial index (ABI), coronary artery calcium (CAC) score, cardio-
respiratory fitness, apolipoprotein B (ApoB), micro-albuminuria, and genetic risk 
markers.
2.2.1 Fast resting heart rate
Several clinical and epidemiological reports have suggested that fast resting 
HR, as a marker of sympathetic nervous system and RAS overactivity, not only is 
a powerful independent predictor of CVD, but also of all-cause mortality. Resting 
faster HR could be associated, through oxidative stress and subsequent inflam-
mation, with development of atherosclerosis, progression of heart failure, and 
enhancement of myocardial ischemia or infarction [31]. In a cross-sectional study 
of Congolese aircrew from both African and Caucasian origin, the proportion of 
subjects with a faster resting HR was of the same magnitude as the 6.8% observed in 
a normative sample from the First U.S. National Health and Nutrition Examination 
Survey (NHANES) I data [32]. It was nearly five times more frequent in flight than 
in cabin crew.
2.2.2 Left ventricular hypertrophy
LVH is an independent predictor of morbidity and mortality including disabling 
events such as sudden death, myocardial infarction and stroke. Echo-based LVH 
is a well-established predictor of CV morbidity and mortality in either the general 
population or high-risk groups. LVH has been found to be the most powerful risk 
factor for sudden death, ventricular arrhythmias, myocardial ischemia, CHD, 
and congestive heart failure. LVH regression due to treatment of hypertension 
predicts an improved prognosis. Abnormal LV geometry in hypertensive patients is 
frequently associated with diastolic dysfunction, which can be further evaluated, 
by a combination of transmitral flow and tissue Doppler studies. Aging–associ-
ated vascular remodeling and insulin resistance with subsequent constellation of 
multiple CVD risk factors might have led to LVH [33] with elevated 10-year global 
cardiovascular risk as observed in our airmen. Insulin resistance and subsequent 
hyperinsulinemia have been reported to activate the sympathetic nervous and the 
renin angiotensin systems resulting in endothelial dysfunction. With reference to 
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Laplace’s law, high blood pressure and obesity could trigger cardiac remodeling 
through hemodynamic and humoral mechanisms and the thickening of cardiac wall 
may occur through collagen deposits. It has been reported that moderate to severe 
LVH, of mainly concentric geometric subtype is a common finding among aircrew 
with age, subclinical atherosclerosis and components of the MetS as its main associ-
ated CV risk factors [34].
2.2.3 Intima media thickness
The determination of cIMT in individual CV risk stratification and target organ 
appears in recent hypertension guidelines because of pathological IMT consistency 
related to future cardiovascular events.
2.2.4 Kidney dysfunction
Chronic kidney disease (CKD) stands as a global public health problem in 
HICs as well as in LMICs. In the USA, the third National Health and Nutrition 
Examination Survey (NHANES III) estimated that the prevalence of CKD has risen 
from 11% between 1988 and 1994 up to 13% between 1999 and 2004 [35, 36]. In a 
systematic review and a meta-analysis from 21 medium- and high-quality studies, 
Stanifer found 13.9% overall prevalence of CKD in SSA [37].
2.2.5 High sensitivity C-reactive protein
Hs-CRP is a marker of inflammation and endothelial dysfunction and sub-
sequent atherosclerosis. It is produced by hepatocytes in response to circulating 
cytokines, particularly IL-6.18. It is also a robust downstream marker of inflam-
mation, although unlikely to have a causative role in CVD. Consequently, the 
relationship between elevated hs-CRP and ASCVD risk remains a matter of con-
troversy. The merit of hs-CRP use is because it does require neither sophisticated 
equipment nor particular operator skills, especially in developing countries. The 
hs-CRP, which is incorporated in the Reynolds score, may provide supplemental 
predictive capacity compared with the FRS [38]. Moreover, the 2013 ACC/AHA 
guidelines on the assessment of CV risk recommend hs-PCR in men (>50 y) and 
in women (>60 y) at intermediate risk, which are qualified for lipid lowering 
drugs [39]. In this regard, many studies reported a robust association of hs-CRP 
with numerous traditional risk factors for CHD such as obesity, diabetes, physi-
cal inactivity, smoking, and alcohol use [40–42]. Other studies highlighted the 
modest relationship between hs-CRP and CVD, because of its variability among 
age, gender (higher magnitude in men), and ethnicity (higher magnitude in 
African Americans vs. Caucasians) [43, 44]. A study comprised of aircrew from 
both African and Caucasian origin reported a net reclassified global ASCVD risk 
based on 2018 ESC/ESH guidelines chiefly in intermediate risk hypertensive 
individuals [40].
2.2.6 Coronary artery calcium
Coronary artery calcium (CAC) a powerful novel risk indicator for ASCVD 
risk. It is linked with an enhanced risk to develop harmful cardiovascular events 
independently of clinical markers and inflammatory biomarkers [45]. Conversely, a 
calcium artery score of 0 has a strong negative predictive value for the development 
of coronary artery diseases (CAD).
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2.2.7 Genetic risk scores
Genetic risk scores have been proposed because of the association between loci 
or genes and higher ASCVD risk. The advantage of genetic biomarkers on other 
biomarkers is that they exist at birth and can be determined even in antenatal 
period. But, gene–environment interactions can sometimes be responsible for 
development of disease states. Furthermore, using new variables such as genetic 
markers may enhance CV prediction even if this possibility remains questionable 
[46]. In a post-hoc meta-analyze of six systematic reviews on effect of ASCVD risk 
estimate in primary prevention, Collins et al. reported that there was no evidence 
that the potential use of ASCVD risk estimate leads to decreasing in CVD morbidity 
and mortality due to the deficient quality of systematic reviews.
3. Global cardiovascular risk estimate in aircrew
3.1 Global cardiovascular risk estimate using traditional risk factors
Given that risk factors for CVDs do not act in isolation, quantification of risk is 
an important part of the risk stratification process. The prediction of an individual’s 
ASCVD risk over a one 10-y period traditionally involves assessment of CVD risk 
factors such as age, gender, baseline levels of systolic and diastolic BP, serum choles-
terol, smoking status and history of diabetes. Published in 1998 [47] and modified 
in 2002 [48], the Framingham risk score (FRS) derived from the Framingham Heart 
Study (FHS) which is broadly granted as the pioneering longitudinal cohort study 
[49, 50]. FHS chart, a risk prediction model, assigns weight (points) to traditional 
risk factors for ASCVD such as age, total cholesterol (TC), high-density lipoprotein 
cholesterol (HDL-c), treated or untreated SBP (yes or no), smoking status (yes or 
no), and type-2 diabetes (yes or no). This FHS chart produces an estimate (or risk) 
of developing CVD or a component of CVD (such as stroke, peripheral vascular 
disease, or heart failure) over a fixed time, for example, the next 10 years [50]. Also, 
Framingham investigators presented heart /vascular age which is the age that cor-
responds to a person with normal risk factors and the same 10-year CV risk stating 
that low 10-year risk can cohabit with a vascular age higher than the chronological 
one [51]. FHS chart has been broadly utilized for clinical guidelines [52], trans-
ported, and validated in several non-Framingham settings [53].
Besides the Framingham estimate functions, other significant risk functions 
such as the European Systematic Coronary Risk Evaluation (SCORE) function, 
the Prospective Cardiovascular Münster (PROCAM) function [53], the QRISK 
[54, 55] algorithms, the Reynolds risk score [56, 57], the Multi Ethnic Study of 
Atherosclerosis (MESA) algorithms may be used [58]. The final objective of all 
these ASCVD risk prediction models should be to improve clinical guidelines in 
detecting silent and undiagnosed CVD. Nevertheless, there are some caveats to 
using these risk factors alone in a model as prognostic tools for CVD risk prediction. 
Most of these risk equations have been constructed with data from Western popula-
tions, are generally population-specific, and may not be safely extrapolated to other 
populations. One must consider the fact that the calculated risk does not mean the 
occurrence of event in any specific individual but rather in 100 individuals with 
identical features.
For aviation personnel, rigorous medical scrutiny leads to the exclusion of 
those with evident CVDs at either initial or renewal of their medical licenses [2]. 
CVD events are often silent or may present without warning. All the licensed 
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aviation personnel undergo CV assessment including electrocardiogram (ECG), 
echocardiography, and lipid profile at initial. An ECG can be done at renewal as 
appropriate.
Several Civil Aviation Authorities (CAA) highly recommend aircrew, chiefly 
those aged 40 years or more, to periodically be screened for cardiovascular risk 
using suitable risk investigative tools that comprise family history and non-fatal 
and fatal end points, and a resting ECG. For most aircrew, the Reynold’s risk 
equation provides a reasonably well-calibrated risk estimate, which includes family 
history [57]. The assessment and management of aeromedical risk continue to be 
a balancing act between practicality, risk tolerance and the advances of diagnostic 
medicine. The risk, which can be considered as a minimum objective for a large 
public transport aircraft due to medical causes, lies in the region of 10−8 and 10−9 per 
hour or per flight as appropriate.
A single risk matrix cannot reflect the operational impact of a medical event for 
all aircrew roles. To reflect the operational impact of a medical event incorporat-
ing aircrew role, a series of risk matrices that reflect the varying operational risk 
pertinent to specific aircrew role (the third dimension) is required. This led Gray 
et al. to develop a three-sized risk matrix, which embodies discrete aircrew duties: 
(i) aircrew with direct control over the aircraft (ie, pilot, copilot), (ii) aircrew 
personnel with input to navigation or engine/mechanical systems (ie, navigator, 
FEs), and (iii) aircrew responsible for passenger or cargo (ie, loadmasters, cabin 
crew) [4]. Although technically, air traffic controllers (ATCs) are not considered 
crews, they are considered to have an attributable risk similar to that of pilots.
Thus, ICAO asks stakeholder countries to use ASCVD estimate scores in aero-
medical risk assessment to help alleviating morbidity and mortality in aeronautical 
setting. For example, the New Zealand Guideline Group (NZGG) adjusted [59], 
updated [60], and even assessed [61] the Framingham ASCVD estimate tools. In 
a matched case–control study accounting Oceania- based airline pilots using the 
NZGG adjusted Framingham score, Wirawan posited the NZGG score had low 
sensitivity and thus missed to predict 47% of the CV events [62].
3.2 Global cardiovascular risk estimate using new and emergent risk factors
Risk in CVD is still assessed chiefly by clinical features such as age, hyperten-
sion, diabetes mellitus, hyperlipidemia, and family history. Nonetheless, biochemi-
cal, cellular, and imaging frameworks are firmly allowing for increasingly improved 
risk assessment.
Aircrew undergo various investigations to assess cardiovascular risk that are 
anatomical (Cardiac CT, cardiac MR or invasive coronary angiography, transtho-
racic and transesophageal echocardiography), physiological (Myocardial perfusion 
imaging, including perfusion MRI, myocardial perfusion scintigraphy [MPS], both 
single photon emission CT [SPECT] and positron emission tomography [PET]), 
stress echocardiogram (with either physiological or pharmacological stress) and 
fractional flow reserve (FFR) and Clinical (Exercise stress ECG test, CAC scor-
ing). Exercise stress ECG test is not recommended as a solely investigative tool for 
assessment of significant CAD in aircrew [63]. It is relevant to note that the negative 
predictive value (NPV) of the CCT for the detection of CHD is almost 100%, which 
implies that a negative scanner is very reassuring at least for the next 35 years [64].
To comply with the approach of the ICAO, it is recommended to CAAs to hold 
an inventory of the effective of aircrew to monitor their careers and health, their 
accidents and impairments [65]. Even for private aircrew, there are concerns, which 
imply that some degree of restriction must be applied. On the other hand, several 
CAAs prohibit pilots aged 65y or older from flying on commercial flight operations 
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even if this remains debatable [63]. The so-called “age-65 rule” is of concerns about 
the potential deleterious effects of aging on pilots’ safety performance [66].
Aircrew with elevated cardiovascular risk established on inceptive screening 
should go through intensified screening that includes ancillary, to name but a 
few, stress ECG, CAC scoring solely, or combined with a CT coronary angiogram 
(CTCA) investigation, and vascular ultrasound imaging (VUI). Second-line 
investigative risk tools for CAD assessment comprise functional imaging, and 
invasive coronary angiography (ICA). Emerging technologies comprise CMR for 
plaque imaging and FFR that is a technique traditionally used as an adjunct to ICA 
to measure pressure differences across coronary stenosis.
Exercise stress ECG provides useful risk-stratification information including 
aerobic fitness, BP response and arrhythmia assessment, which may be incorpo-
rated in intensified screening. The use of routine exercise stress testing as a sole 
screening tool for CAD is not supported by evidence and is not recommended. 
Exercise stress tests are limited in their ability to detect potentially flow-limiting 
CAD and to predict future cardiovascular events. Because of its restricted sensitiv-
ity and specificity, exercise stress ECG has a flaw as screening test for coronary 
atherosclerosis. Moreover, because of its very low PPV for future coronary events, 
stress ECG should be discouraged as a stand-alone tool to determine aeromedically 
significant CAD.
The Astro-CHARM tool is the first integrated ASCVD risk calculator to incorpo-
rate risk factors, including hs-CRP, family history, and CAC data. It improves risk 
prediction in comparison with traditional risk factor equations and could be useful 
in risk-based decision making for cardiovascular disease prevention in the middle-
aged general population.
Ultrasound imaging of the carotid and femoral arteries provides easily accessible 
visualization of vascular anatomy without radiation. cIMT and carotid and femoral 
artery plaque, have been evaluated as markers for cardiac disease and stroke risk. 
Several prospective studies have shown that the presence of carotid and femoral 
bifurcation plaques is associated with future cardiovascular events, independent 
of other risk factors. Guidelines support the use of carotid artery ultrasound in the 
cardiovascular risk assessment of asymptomatic aircrew at intermediate risk.
To identify aeromedically significant CAD, physiological imaging such as stress 
echo, perfusion MRI or myocardial perfusion scintigraphy (MPS) has limited utility 
and is not recommended as the sole secondary investigation for aircrew consid-
ered to be at high cardiovascular risk as it may overlook aeromedically significant 
(aggregate) stenosis. ICA should be reserved for those aircrew who are deemed at 
high risk for significant CAD or where accurate delineation of percentage coronary 
stenosis is required. ICA currently remains the gold standard for anatomical imag-
ing of coronary arteries. This is because the spatial resolution of ICA is superior to 
that of CTCA. CTCA is less accurate than ICA for quantifying luminal stenosis. The 
threshold for initiating enhanced screening of aircrew with increased estimated risk 
for a coronary event is an organizational decision.
4. Preventing cardiovascular disease
Aircrew retirement age is increasing and the burden of subclinical, but poten-
tially significant, coronary artery atherosclerosis is unknown in pilots above age 
40 [20]. Prevention of CVD in aircrew may be even more problematic than in the 
general population. The control of CVD should focus on the reduction of behavioral 
risks (salt, tobacco, alcohol, physical inactivity) and metabolic risks (high BP, dia-
betes mellitus, and obesity), and on multidrug therapy for treatment of individuals 
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at high risk of heart attack and stroke based on these risks. Preventive initiatives 
should make it easier for healthy aircrew to stay healthy, and for those with estab-
lished CVD or at high risk for CVD to modify their behavior [67]. To prevent the 
onset of CVD in aircrew, many avenues including healthier lifestyle such as regular 
physical activity, healthier diet, weight loss, moderate alcohol consumption, and 
smoking cessation, and the control risk factors can be considered.
Regular physical activity lowers the risk of CVD, improves endothelial and plate-
let function, and diminishes insulin resistance [68]. In fact, regular physical activity 
corrects raised BP and lipid profile, increases the level of HDL but lowers that of TC 
and LDL-c [68–70]. NICE guidelines recommend 150 minutes of moderate inten-
sity aerobic activity per week, or 75 minutes of vigorous aerobic activity. Whilst 
NICE give only a consensus recommendation regarding the utility of exercise as 
primary prevention, guidelines from the AHA and ESC give class 1A recommenda-
tions with almost identical prescriptions, referring to a solid and consensual body 
of evidence [17, 71]. It has been reported in a recent cross-sectional study including 
22 physically active men, exempt from CVD, that particular features of physical 
fitness such as aerobic capacity were associated with better cardiovascular control 
(HRV and BP) during flights. These authors encouraged future studies to inves-
tigate the role of physical fitness in reducing the flight-induced stress and related 
cardiac autonomic alterations for the general population [20].
Diet represents the most significant modifiable factor in the primary preven-
tion of CVD. There is evidence that eating fruit and vegetables have been found to 
have compelling cardiovascular effects [69]. Epidemiological evidence shows that 
a diet low in fruits is the third most important risk factor of CVDs following high 
BP and cigarette smoking, accounting for more than 5 million deaths worldwide in 
2010 [72]. The mechanisms of action mainly included the modulation of molecular 
events and signaling pathways associated with correcting endothelial dysfunction, 
reducing disorders in lipids metabolism, anti-hypertension, suppressing platelet’s 
function, alleviating I/R injury, inhibiting thrombosis, reducing oxidative stress, 
and inhibiting inflammation responses [73]. Several studies have highlighted the 
impact of high-potassium diet on high BP, singularly in the presence of high dietary 
sodium, using the inward-rectifying potassium (Kir) [74].
There is evidence that modest weight loss (e.g., 5–10%) can reduce CVD risk 
profile even when the patient remains in the obese range [75, 76]. Modest weight 
loss has been linked with an improvement in fasting glycaemia, glycosylated 
hemoglobin (HBA1c), and systolic and diastolic BP and plasma lipid profile (TG, 
TC, and LDL-c) [77]. Moreover, weight loss can also improve the efficacy of anti-
hypertensive medications. Weight loss should employ a multidisciplinary approach 
that includes dietary advice, regular exercise, and motivational counseling [17, 78]. 
Weight loss can also be promoted by anti-obesity drugs and, to a greater degree, 
bariatric surgery, which appears to decrease CV risk in severely obese patients [79]. 
There are moves to suggest that, alongside reduction in BMI, reduction in WC as a 
proxy for reductions in visceral adiposity should become an important target for 
amelioration of CVD risk.
Four decades ago, epidemiological studies showed the historically J-shaped 
curve between alcohol consumption and cardiovascular risk [80, 81]. Recently, 
both cohort studies and meta-analyses corroborated the robustness of the men-
tioned relationship [82]. These authors argued that abstinence is associated with an 
increase in cardiovascular risk compared to light drinking and low levels of alcohol 
consumption associated with a lower level of CHD. Similarly, INTERHEART, NICE, 
and ACC studies showed moderate to light alcohol use was linked with prevent-
ing CVD. Contrastingly, through a large mendelian randomization meta-analysis, 
Holmes et al. showed that reduction in alcohol intake is linked with reduction 
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in CVD risk even in light-moderate drinkers [83]. It is on this basis that the ESC 
guidelines recommend no safe level of alcohol intake [84].
Smoking cessation is strongly recommended by all guidelines and smoker is 
likely to use nicotine replacement therapy (NRT), bupropion (a norepinephrine 
dopamine reuptake inhibitor) and particularly varenicline (a partial nicotine recep-
tor agonist). Evidence suggests the use of NRT outweigh its cardiovascular risks 
whilst the use of E-cigarettes are still controversial [85].
Lowering BP to an optimal level (<130/80 mmHg) has been found to signifi-
cantly reduce the risk of CVD [86]. Best proven non pharmacologic Interventions 
for prevention and treatment of hypertension that are weight loss, health diet, 
lower intake of dietary Na+, enhanced intake of dietary K+, physical exercise, 
and moderate alcohol intake approximately impact on SBP by 5, 11, 6, 5, 5, and 
4 mmHg, respectively. Specific BP lowering drugs include calcium blockers, diuret-
ics, ACEI, ARBS, and beta-blockers [84]. Medical practitioners are advised to avoid 
pharmacological inertia characterized by negligence of medical providers to initiate 
or intensify pharmacological therapy as stated by guidelines [84].
The overall strategy toward risk management for type-2 diabetes patients 
should focus on BP and lipid control to lower the leading complications of diabetes. 
Diabetes is treated with diet, exercise, and some antidiabetic medications [87]. 
Lowering cholesterol by means of drugs such as statins alone or associated with 
either ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) 
monoclonal antibodies (mAbs), has been found to reduce ASCVD risk; however, 
lipid-lowering diet and physical exercise are also important [88].
In aircrew with heart failure, medications should include B-adrenergic blockers, 
ACEIs, and more recently Ivabradine and/or sacubitril/ valsartan combination, 
when appropriate. Implantable cardioverter defibrillators and/or resynchronization 
should be associated. Exercise training is usually indicated based on the patient 
response to applied exercise protocols. In patients with CKD, risk factors such as 
hypertension, type-2 diabetes, and obesity should be controlled [89].
Traditional herbal remedies should be avoided for numerous riveting studies 
showed their toxicity even if histological and toxicological studies are needed to 
validate this causal relationship [89]. Antihypertensive treatment reverses myocar-
dial hypertrophy, and additionally reduces repolarization time and its dispersion, 
the incidence and the severity of ventricular arrhythmia, and the risk of cardiovas-
cular events.
Flight crew represent a high CVD risk subgroup requiring development of a 
comprehensive prevention and care program to mitigate the elevated risk and 
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